Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000266466, referred to as "Novel transcript, antisense to C17orf51," is annotated as a long non-coding RNA (lncRNA) gene. It is designated as "novel" because it does not correspond to an established protein-coding gene and is transcribed from the DNA strand opposite to the C17orf51 gene locus. There is no experimental evidence describing its function, disease association, or potential as a drug target. The entry is essentially a cataloged transcript with unknown or unstudied biological relevance. No functional, clinical, or therapeutic data are available for this entry, which is typical for many lncRNAs annotated as "novel transcripts" in genome databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to C17orf51.